Status:
COMPLETED
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
Lead Sponsor:
Tanabe Pharma Corporation
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
20-65 years
Phase:
PHASE3
Brief Summary
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who relapsed after previous treatment.
Eligibility Criteria
Inclusion
- Genotype 2, chronic hepatitis C
- Relapsers (patient who relapsed after previous treatment)
- Able and willing to follow contraception requirements
Exclusion
- Cirrhosis of the liver or hepatic failure
- Hepatitis B surface antigen-positive or HIV antibodies-positive
- History of, or concurrent hepatocellular carcinoma
- History of, or concurrent depression, schizophrenia,; or suicide attempt in the past
- Pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant
Key Trial Info
Start Date :
May 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT01466192
Start Date
May 1 2012
End Date
August 1 2013
Last Update
January 6 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toranomon Hospital
Minato-ku, Tokyo, Japan